Maintenance chemotherapy with oral treosulfan following first-line treatment in patients with advanced ovarian cancer: Feasibility and toxicity

Anticancer Research

Volumn 17, Issue 3 C, 1997, Pages 2221-2223

  Meden, Harald ^a,b   Wittkop, Yvonne ^a   Kuhn, Walther ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY OF HAMBURG   (Germany)

Author keywords

Chemotherapy; Oral treatment; Ovarian cancer; Treosulfan

Indexed keywords

SULFONIC ACID DERIVATIVE; TREOSULFAN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG TOLERABILITY; FEMALE; HUMAN; LEUKOPENIA; MAINTENANCE THERAPY; ORAL DRUG ADMINISTRATION; OVARY CANCER; PRIORITY JOURNAL; THROMBOCYTOPENIA;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BUSULFAN; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; FEMALE; HUMANS; LEUKOPENIA; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; SURVIVAL ANALYSIS; THROMBOCYTOPENIA; TIME FACTORS;

EID: 0030846530     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Benedetti-Panici P, G Scambia, G Greggi et al.: Doxorubicin and cyclophosphomide alternated with bleomycin and mitomycin C as a second-line regimen in advanced ovarian cancer resistant to cisplatin-based chemotherapy. Oncology 47: 296-298, 1990.
2. Burghardt E, H Pickel, M Lahousen: Pelvic lymphadenactomy in operative treatment of ovarian cancer. Am J Obstet Gynecol 155: 315-319, 1986.
3. Duncan ID, LA Clayton: Combination chemotherapy of ovarian carcinoma with cisplatinum and treosulfan - A phase II study. Br J Obstet Gynecol 92: 762-767, 1985.
4. Eisenhauer EA, Huinink WWB, Swerton KD et al: European- Canadian randomized trial of taxol relapsed ovarian cancer. High vs low dose and long vs short infusion. J Clin Oncol 12: 2654-2666, 1994.
5. Einzig AI, PH Wiernik, J Sasloff et al: Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. J Gin Oncol 10: 1748-1753, 1992.
6. Feit PW: Stereoisomere 1,4-di-O methanesulfonyl-butan-1,2,3,4,-tetrole. Tetrahedron Lett 20: 716-718, 1961
7. Fennelly JJ: Treosulfan (Hydroxybusulfan) in ovarian carcinoma. Current Chemotherapy And Infectious descase: 1683-1684, 1980
8. Hoskins PJ, E McMurtrie, KD Swenerton: A phase II trial of intravenous etoposide (VP-16-213) in epithelial ovarian cancer resistant to cisplatin or carboplatin: Clinical and serological evidence of activity. Int J Gynecol Cancer 2: 35-40, 1992
9. Kramer D, Golz N, D Glaser et al.: Treosulfan als Second-Line-Chemotherapie beim fortgeschrittenen Ovarialkarzinom. Archives Gynecol Obstet; Vol 2 1-4: 195-196, 1991.
10. Manetta A, C MacNeill, JA Lyter et al.: Hexamethylmelamine as a single second-line agent in ovarian cancer. Gynecol Oncol 36: 93-96, 1990.
11. McGuire WP, EK Rowinsky, NB Rosenhein et al: Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111: 273-279, 1989.
12. Meden H, A Metz, E Mωnkeberg-Tun, W Kuhn: The quality of life of patients with ovarian cancer after surgery and chemotherapy. Oncologie 16: 50-56, 1993.
13. Meden H, D Marx, W Rath et al: Overexpression of the oncogene c-erbB-2 in primary ovarian cancer: Evaluation of the prognostic value in a Cox proportional hazards multiple regression. Int J Gynecol Pathol 13: 45-53, 1994.
14. Meden H, W Rath, A Teichmann: Lymphadenectomy and retroperitoneal lymph node metastases in ovarian cancer. J Cancer Res Clin Oncol 116: 693, 1990.
15. Meden H, W Rath, W Kuhn: Taxol - A new cystostatic agent for the treatment of ovarian and breast cancer. Geburtsh. u. Frauenheilk 53: 187-193, 1994.
16. Neijt JP, WW ten Bokkel Huinink, MEL van der Burg et al: Randomized trial comparing two combination chemotherapy regimes (CHAP-5 vs CP) in advanced ovarian carcinoma. J Clin Oncol 5: 1157-1168, 1987.
17. Neijt JP: Treatment of advanced ovarian cancer: Ten years of experience. Ann Oncol 3: 17-27, 1992.
18. Sutton GP, JA Blessing, HD Homesley et al: Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 8: 1672-1676, 1989.
19. Trimble EL, JD Adams, D Vena et al: Taxol in patients with platinum-resistant ovarian cancer (meeting abstract). Proc Am Soc Clin Oncol 12: 261, 1993.
20. th International Congress of Chemotherapy 1981; Volume II: 1335-1337.
21. WHO (1979): WHO Handbook for reporting Results of Cancer Treatment. Geneva: World Health Organization Offset Publication No. 48.